Cointime

Abliva AB

company

About

Abliva develops medicines for the treatment of primary mitochondrial diseases.

  • 1 - 10

Highlights

Total Funding Amount
$4.09M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$4.09M
Industries
Biotechnology,Clinical Trials,Health Care
Founded date
Jan 1, 2000
Number Of Employee
1 - 10
Operating Status
Active

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$4.09M
Abliva AB has raised a total of $4.09M in funding over 2 rounds. Their latest funding was raised on Aug 29, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 29, 2018 Grant $4.09M 1 Congressionally Directed Medical Research Programs — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Abliva AB is funded by 1 investors. Congressionally Directed Medical Research Programs are the most recent investors.
Investor Name Lead Investor Funding Round
Congressionally Directed Medical Research Programs Yes Grant
Cointime
เนื้อหา
บริษัท